S&P Futures
4,134.25 -12.50 (-0.30%) Dow Futures
32,685.00 -72.00 (-0.22%) Nasdaq Futures
13,184.50 -44.25 (-0.33%) Russell 2000 Futures
1,915.80 -6.00 (-0.31%) Crude Oil
88.01 -1.00 (-1.12%) Gold
1,790.30 -0.90 (-0.05%)
BioMarin Pharmaceutical Inc. (BMRN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 92.98 |
| Open | 91.90 |
| Bid | 95.90 x 800 |
| Ask | 99.97 x 2200 |
| Day's Range | 91.65 - 96.50 |
| 52 Week Range | 70.73 - 96.50 |
| Volume | |
| Avg. Volume | 1,190,782 |
| Market Cap | 17.772B |
| Beta (5Y Monthly) | 0.33 |
| PE Ratio (TTM) | 330.41 |
| EPS (TTM) | 0.29 |
| Earnings Date | Oct 25, 2022 - Oct 31, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 111.95 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BMRN
Related Research
- BioMarin Pharmaceutical Inc.Analyst Report: BioMarin Pharmaceutical Inc.BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.RatingFair ValueEconomic Moat2 days agoMorningstar
- Benzinga
BioMarin Lifts Annual Guidance On Better Than Expected Q2 Earnings
BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Q2 sales reached $533.8 million, up 6% Y/Y, beating the consensus of $521.47 million. BioMarin said the increase was achieved "despite continued erosion of the U.S. Kuvan market." Total revenues grew 13% Y/Y, excluding Kuvan. The company reported EPS of $0.15 compared to $0.07 a year ago, beating the consensus of $0.11. Voxzogo for achondroplasia (dwarfism) reported sales of $34.4 million. An estimated 446 children were being treated with commercial V
- Zacks
BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales
Biomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.
- Zacks
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
